Faculty Profiles - ONISHI Hideki

Papers - ONISHI Hideki

Division display 81 - 89 of about 89 ／ All the affair displays >>

Loss of runt-related transcription factor 3 expression leads hepatocellular carcinoma cells to escape apoptosis. Reviewed International journal

Yutaka Nakanishi, Hidenori Shiraha, Shin-ichi Nishina, Shigetomi Tanaka, Minoru Matsubara, Shigeru Horiguchi, Masaya Iwamuro, Nobuyuki Takaoka, Masayuki Uemura, Kenji Kuwaki, Hiroaki Hagihara, Junichi Toshimori, Hideki Ohnishi, Akinobu Takaki, Shinichiro Nakamura, Yoshiyuki Kobayashi, Kazuhiro Nouso, Takahito Yagi, Kazuhide Yamamoto

BMC cancer 11 3 - 3 2011.1

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: Runt-related transcription factor 3 (RUNX3) is known as a tumor suppressor gene for gastric cancer and other cancers, this gene may be involved in the development of hepatocellular carcinoma (HCC). METHODS: RUNX3 expression was analyzed by immunoblot and immunohistochemistry in HCC cells and tissues, respectively. Hep3B cells, lacking endogenous RUNX3, were introduced with RUNX3 constructs. Cell proliferation was measured using the MTT assay and apoptosis was evaluated using DAPI staining. Apoptosis signaling was assessed by immunoblot analysis. RESULTS: RUNX3 protein expression was frequently inactivated in the HCC cell lines (91%) and tissues (90%). RUNX3 expression inhibited 90±8% of cell growth at 72 h in serum starved Hep3B cells. Forty-eight hour serum starvation-induced apoptosis and the percentage of apoptotic cells reached 31±4% and 4±1% in RUNX3-expressing Hep3B and control cells, respectively. Apoptotic activity was increased by Bim expression and caspase-3 and caspase-9 activation. CONCLUSION: RUNX3 expression enhanced serum starvation-induced apoptosis in HCC cell lines. RUNX3 is deleted or weakly expressed in HCC, which leads to tumorigenesis by escaping apoptosis.

DOI： 10.1186/1471-2407-11-3

PubMed

researchmap

Time-dependent analysis of predisposing factors for the recurrence of hepatocellular carcinoma. Reviewed International journal

Shouta Iwadou, Kazuhiro Nouso, Kenji Kuwaki, Yoshiyuki Kobayashi, Shinichiro Nakamura, Hironori Tanaka, Kenji Miyoshi, Hideki Ohnishi, Yasuhiro Miyake, Hidenori Shiraha, Yoshiaki Iwasaki, Yasushi Shiratori, Kazuhide Yamamoto

Liver international : official journal of the International Association for the Study of the Liver 30 ( 7 ) 1027 - 32 2010.8

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND/AIM: There are many reports dealing with the risk factors for hepatocellular carcinoma (HCC) recurrence. However, in most of these reported studies, factors were analysed only at the initial treatment stage, and the predisposing factors for the recurrence during follow-up have not been well studied. The aim of this study is to evaluate the predisposing factors after treatments. METHODS: Two hundred and seventy-one consecutive HCC patients curatively treated between January 1994 and March 2004 were followed up and analysed. The recurrence rate was estimated by the Kaplan- Meier method and the predisposing factors were evaluated by time-fixed Cox regression analysis and by time-dependent covariate analysis using multiple parameters. RESULTS: The mean follow-up period was 4.86 years and recurrence was observed in 169 patients (62.4%). The recurrence rates were 27.9, 65.1 and 84.3% at 1, 3 and 5 years respectively. Among the variables determined before treatment, predisposing factors for recurrence were low serum albumin [< or =3.5 g/dl, hazard ratio (HR)=1.47, 95% confidence interval (CI)=1.07-2.01] and multiple tumour number (HR=2.04, 95% CI=1.46-2.84) by time-fixed multivariate analysis. In the time-dependent analysis, six variables with 12 013 plots were examined. The multivariate analysis revealed that high des- gamma-carboxy prothrombin (DCP > or =40 mAU/ml, HR=2.33, 95% CI=1.61-3.39), high alpha-fetoprotein (AFP > or =100 ng/ml, HR=2.01, 95% CI=1.3-3.35) and high alanine aminotransferase (ALT > or = 40 IU/L, HR= 1.52, 95% CI=1.1-2.1) were significant predisposing factors for recurrence. CONCLUSION: Predisposing factors for the recurrence of HCC after treatment are different from those before treatments and special cautions are required when AFP, DCP or ALT is high during follow-up.

DOI： 10.1111/j.1478-3231.2010.02252.x

PubMed

researchmap

Outcome of small liver nodules detected by computed tomographic angiography in patients with hepatocellular carcinoma. Reviewed International journal

Hideki Ohnishi, Kohsaku Sakaguchi, Kazuhiro Nouso, Yoshiyuki Kobayashi, Shinichiro Nakamura, Hironori Tanaka, Yasuhiro Miyake, Bon Shoji, Shouta Iwadou, Yasushi Shiratori

Hepatology international 4 ( 3 ) 562 - 8 2010.7

Authorship：Lead author,　Corresponding author Language：English Publishing type：Doctoral thesis

PURPOSE: Hepatic lesions identified by computed tomography (CT) during arterial portography (CTAP) or CT hepatic arteriography (CTHA) in hepatocellular carcinoma (HCC) patients are sometimes too small to be diagnosed as HCC. We undertook this cohort study to assess whether these small lesions are actually HCC, and to clarify the effectiveness of these imaging examinations in a clinical setting. METHODS: We assessed the characteristics of 74 tiny lesions detected by CTAP and/or CTHA, but not by CT in 67 patients. RESULTS: Seven out of 10 nodules were histologically confirmed as HCC and 18 out of 64 lesions increased in size and showed typical findings of HCC during the follow-up period. Multivariate analysis revealed that the size of the main tumor (>30 mm in diameter) was associated with the presence of tiny additional HCC lesions (P = 0.002). CONCLUSIONS: These findings indicate that CTAP and CTHA are recommended for determining the stage of HCC, especially when the HCC nodule is larger than 30 mm in diameter.

DOI： 10.1007/s12072-010-9190-6

PubMed

researchmap

Evolution of prognostic factors in hepatocellular carcinoma in Japan Reviewed

K. Nouso, Y. Kobayashi, S. Nakamura, S. Kobayashi, J. Toshimori, K. Kuwaki, H. Hagihara, H. Onishi, Y. Miyake, F. Ikeda, H. Shiraha, A. Takaki, Y. Iwasaki, H. Kobashi, K. Yamamoto

ALIMENTARY PHARMACOLOGY & THERAPEUTICS 31 ( 3 ) 407 - 414 2010.2

Language：English Publishing type：Research paper (scientific journal) Publisher：WILEY-BLACKWELL PUBLISHING, INC

P>Background
The surveillance of hepatocellular carcinoma (HCC) has become prevalent, and the modalities for its treatment have improved.
Aim
To understand the changes that occur in the characteristics and prognostic factors of HCC with time.
Methods
Newly diagnosed HCC patients were divided into two groups; patients treated before 31 December 2000 (n = 504), and after 1 January 2001 (n = 746), and their clinical backgrounds and prognostic factors were analysed.
Results
The number of patients negative for both Hepatitis B surface antigen (HBsAg) and Hepatitis C virus antibody (HCVAb) increased with time (NBNC-HCC). The size of HCC decreased in patients who were positive for HBsAg (B-HCC) or HCVAb (C-HCC), whereas no difference was observed in NBNC-HCC. The patient survival of C-HCC improved; however, no difference was detected for NBNC-HCC. In multivariate analysis, low albumin, high aspartate aminotransferase (AST), ascites, large tumour size, multiple tumour number and high alpha-fetoprotein were risk factors for survival before 2000, whereas the presence of HBsAg was additionally selected as a good prognostic factor and AST was excluded after 2001.
Conclusions
The prognostic factors as well as clinical background of HCC changed with time, and the presence of HBsAg was found to be an additional good prognostic factor after 2001.

DOI： 10.1111/j.1365-2036.2009.04179.x

Web of Science

PubMed

researchmap

Evidence-based clinical practice guidelines for hepatocellular carcinoma Invited

121 ( 1 ) 41 - 45 2009

FDG-PET/CTで異常集積を示し、CT、MRIでリング状に造影されたangiomyolipoma(AML)の1例 Reviewed

衣笠秀明, 土井顕, 大西秀樹, 三好正嗣, 金吉俊彦, 池田弘, 下村宏之, 山本博, 篠浦先, 八木孝仁

Liver Cancer 14 ( 1 ) 97 - 105 2008.4

Language：Japanese Publishing type：Research paper (scientific journal) Publisher：(株)アークメディア

42歳女。健診で肝腫瘤を指摘された。腹部超音波でS7に孤立性の比較的境界明瞭な14×10mmの低エコー腫瘤を認め、内部は一部高エコーであった。カラードプラでは腫瘤内に拍動性の血流信号を認め、背景は軽度の脂肪肝であった。腹部CTで腫瘤は等吸収域を示し、造影では早期相でリング状に造影され、経時的に内部も造影、後期相でwash outされた。腹部MRIでは拡散強調像で高信号、ADCで低信号、T2強調像で等信号、T1強調像で低信号、造影所見はCTと同様であった。FDG-PET/CTでは腫瘤に一致して集積亢進を認めた。胆管細胞癌を最も疑い、診断的治療として肝切除術を施行した。病理組織所見で、胞体が淡明化した紡錘型細胞が束状、密に増殖しており、わずかに小血管の増生も認めた。脂肪組織の混在はほとんどなかったが、免疫染色で腫瘍細胞はHMB45陽性、α-smooth muscle actin陽性で、angiomyolipomaと診断した。

researchmap

Other Link： https://search.jamas.or.jp/default/link?pub_year=2008&ichushi_jid=J02969&link_issn=&doc_id=20080502080013&doc_link_id=%2Fab8livec%2F2008%2F001401%2F013%2F0097-0105%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8livec%2F2008%2F001401%2F013%2F0097-0105%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

多発肝細胞癌の治療後にインターフェロン療法を行い、HCV-RNA消失と12年間無再発生存を維持したC型肝炎の1例 Reviewed

香川幸一, 池田弘, 衣笠秀明, 尾崎由直, 濱口京子, 大西秀樹, 金吉俊彦, 下村宏之, 山本博, 朴泰範

Liver Cancer 14 ( 1 ) 27 - 34 2008.4

Language：Japanese Publishing type：Research paper (scientific journal) Publisher：(株)アークメディア

72歳男。60歳時にC型肝炎に対するインターフェロン(IFN)療法目的で入院した際、肝S6・S7・S8に8～10mmの高エコーSOLを認めた。生検所見でS6・S8のSOLはcellularityが高く高分化型肝細胞癌(HCC)、S7のSOLは脂肪化を伴うhyper-plastic lesionと診断され、非腫瘤部はchronic aggressive hepatitisであった。経皮的エタノール注入療法を行い、その後IFN-α2aの24週投与を行ったところ、ウイルス消失が達成された。HCV-RNA陰性が持続していたが、12年後のMRIでS8に25mm大のT1強調像で低信号、T2強調像で高信号、造影でhypervascularな再発巣を認めた。DSAではS8のドーム下に腫瘍濃染を認め、CT arterial portographyではdefectとして認められた。HCC再発と診断し切除を行い、切除後病理所見で病変部は中分化型HCC、LoA単純結節型であった。免疫組織学的にはPIVKA-IIがびまん性に陽性、AFPはfocalに陽性細胞を認めた。非癌部は偽小葉を認め、肝硬変像を呈していた。

researchmap

Other Link： https://search.jamas.or.jp/default/link?pub_year=2008&ichushi_jid=J02969&link_issn=&doc_id=20080502080004&doc_link_id=issn%3D1341-1926%26volume%3D14%26issue%3D1%26spage%3D27&url=http%3A%2F%2Fwww.pieronline.jp%2Fopenurl%3Fissn%3D1341-1926%26volume%3D14%26issue%3D1%26spage%3D27&type=PierOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00005_2.gif

Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances. Reviewed International journal

Kazuhiro Nouso, Hironori Tanaka, Shuji Uematsu, Kunihiro Shiraga, Ryoichi Okamoto, Hideki Onishi, Shin-Ichiro Nakamura, Yoshiyuki Kobayashi, Yasuyuki Araki, Noriaki Aoki, Yasushi Shiratori

Journal of gastroenterology and hepatology 23 ( 3 ) 437 - 44 2008.3

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND AND AIM: The clinical features of hepatocellular carcinoma (HCC) and the medical environment are diverse in different geographic areas. The aim of this study is to evaluate the cost-effectiveness of the surveillance of HCC in different medical circumstances. METHODS: The Markov model focused on variables that differ from country to country and may change in the future, especially in regards to the proportion of small HCC detected incidentally. The target population was 45-year-old patients with Child-Pugh class A cirrhosis, and the intervention was surveillance with ultrasonography every 6 months. RESULTS: The additional cost of the surveillance was $US15 100, the gain in quality-adjusted life years (QALYs) was 0.50 years, and the incremental cost-effectiveness ratio (ICER) was $US29 900/QALY in a base-case analysis (annual incidence of HCC = 4%). If 40% of small HCC were detected incidentally without surveillance, the gain in QALY decreased to 0.15 and the ICER increased to $US47 900/QALY. The increase in the annual incidence of HCC to 8% resulted in the increase of QALYs to 0.81, and the decrease of the ICER to $US25 400/QALY. The adoption of liver transplantation increased the gain in QALYs and the ICER to 0.84 and $US59 900/QALY, respectively. CONCLUSIONS: The gain in QALYs and the ICER due to the surveillance of HCC varies between different patient subgroups and it critically depends on the rate of small HCC detected incidentally without surveillance, as well as the annual incidence of HCC and the adoption of liver transplantation.

PubMed

researchmap

Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival. Reviewed International journal

Hironori Tanaka, Kazuhiro Nouso, Haruhiko Kobashi, Yoshiyuki Kobayashi, Shin-ichiro Nakamura, Yasuhiro Miyake, Hideki Ohnishi, Kenji Miyoshi, Shouta Iwado, Yoshiaki Iwasaki, Kohsaku Sakaguchi, Yasushi Shiratori

Liver international : official journal of the International Association for the Study of the Liver 26 ( 5 ) 543 - 51 2006.6

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: The benefit of surveillance of hepatocellular carcinoma (HCC) for patients with hepatitis C virus (HCV) infection, in terms of long-term survival, has not yet been established. METHODS: A total of 384 consecutive anti-HCV-positive HCC patients admitted to our hospital between January 1991 and October 2003 were enrolled. Patients were categorized into two groups, a surveillance group (182 patients) and a non-surveillance group (202 patients), according to tumor detection in a surveillance program based on periodical examination via ultrasound sonography and alpha fetoprotein determination at 6-month intervals, and their survival rates were compared. RESULTS: Although there were no significant differences in age and Child-Pugh classes between the two groups, the surveillance group exhibited a smaller tumor size (19 vs. 35 mm) and a higher incidence of single HCC (67% vs. 46%), compared with the non-surveillance group (each, P < 0.001). The cumulative survival rate in the surveillance group was higher than that in the non-surveillance group (5 years survival, 46% vs. 32%, P < 0.001). When the survival after correction of the lead-time bias in the surveillance group was analyzed according to the Child-Pugh classification, the surveillance program was found to have had a favorable outcome in Child-Pugh class A patients, but not in Child-Pugh class B/C patients. CONCLUSIONS: HCC surveillance for patients with HCV infection can lead to discovery of tumors at an early stage, especially in Child-Pugh class A, resulting in a favorable outcome.

PubMed

researchmap

　 PREV - NEXT 　

< ONISHI Hideki >

Papers - ONISHI Hideki